--------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 26, 2005
NEKTAR THERAPEUTICS
(Exact name of Registrant as specified in its charter)
Delaware 0-23556 94-3134940
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
150 Industrial Road
San Carlos, California 94070
(Address of principal executive offices and Zip Code)
Registrant's telephone number, including area code: (650) 631-3100
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
--------------------------------------------------------------------------------
1
Item 5.02 Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers.
(b) On July 26, 2005, the registrant announced that its current Chief Financial
Officer, Mr. Ajay Bansal, would be transitioning from his current duties as
Chief Financial Officer and Vice President, Finance and Administration to the
position of General Manager, Diabetes Group. In connection with his new
position, among other matters, Mr. Bansal will be responsible for overseeing
product decisions, resource allocation and partner relationships. Further,
effective July 26, 2005, the registrant is commencing a search for a new Chief
Financial Officer to succeed Mr. Bansal. Mr. Bansal will continue to serve in
the position of Chief Financial Officer until his successor is identified and
retained by the registrant.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
99.1 News release dated July 26, 2005 of the registrant.
2
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
By: /s/ Nevan Elam
---------------------------------
Nevan Elam
Senior Vice President Corporate
Operations
and General Counsel
Date: July 26, 2005
3
INDEX TO EXHIBITS
99.1 News release dated July 26, 2005 of the registrant.
4